|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-2-14
|
|
pubmed:abstractText |
Pregabalin, a high-affinity ligand for ?2? subunits of voltage-gated calcium channels, is a novel pharmacotherapy for chronic pain, partial seizures, and other disorders. The present study investigated the population pharmacokinetics of pregabalin following single and multiple doses in healthy volunteers and patient populations.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1528-1167
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Wiley Periodicals, Inc. © 2011 International League Against Epilepsy.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
52
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
248-57
|
|
pubmed:meshHeading |
pubmed-meshheading:21269291-Adult,
pubmed-meshheading:21269291-Aged,
pubmed-meshheading:21269291-Algorithms,
pubmed-meshheading:21269291-Analgesics,
pubmed-meshheading:21269291-Anticonvulsants,
pubmed-meshheading:21269291-Chronic Disease,
pubmed-meshheading:21269291-Databases, Factual,
pubmed-meshheading:21269291-Dose-Response Relationship, Drug,
pubmed-meshheading:21269291-Drug Interactions,
pubmed-meshheading:21269291-Epilepsies, Partial,
pubmed-meshheading:21269291-Ethnic Groups,
pubmed-meshheading:21269291-Female,
pubmed-meshheading:21269291-Humans,
pubmed-meshheading:21269291-Male,
pubmed-meshheading:21269291-Middle Aged,
pubmed-meshheading:21269291-Models, Statistical,
pubmed-meshheading:21269291-Nonlinear Dynamics,
pubmed-meshheading:21269291-Pain,
pubmed-meshheading:21269291-Population,
pubmed-meshheading:21269291-Reproducibility of Results,
pubmed-meshheading:21269291-gamma-Aminobutyric Acid
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures.
|
|
pubmed:affiliation |
Neurosciences, Clinical Pharmacology, Pfizer Global Research & Development, New London, Connecticut 06320, USA. howard.bockbrader@pfizer.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
